Brinzolamide plus brimonidine for the treatment of glaucoma: an update

Bibliography

• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90(3):262-7
   PubMed Web of Science ®Google Scholar
• Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998;126(4):487-97
   PubMed Web of Science ®Google Scholar
• Gordon MO, Beiser JA, Brandt JD, et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120(6):714-20. discussion 829-30
   PubMedGoogle Scholar
• Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121(1):48-56
   PubMedGoogle Scholar
• Musch DC, Gillespie BW, Niziol LM, et al. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology 2011;118(9):1766-73
   PubMed Web of Science ®Google Scholar
• Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004;111(9):1627-35
   PubMed Web of Science ®Google Scholar
• The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol 2000;130(4):429-40
   PubMed Web of Science ®Google Scholar
• Khaw PT, Chiang M, Shah P, et al. Enhanced trabeculectomy: the moorfields safer surgery system. Dev Ophthalmol 2012;50:1-28
   PubMedGoogle Scholar
• Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol 2012;153(5):789-803. e2
   PubMed Web of Science ®Google Scholar
• Dashevsky AV, Lanzl IM, Kotliar KE. Non-penetrating intracanalicular partial trabeculectomy via the ostia of Schlemm’s canal. Graefes Arch Clin Exp Ophthalmol 2011;249(4):565-73
   Google Scholar
• Shi JM, Jia SB. Selective laser trabeculoplasty. Int J Ophthalmol 2012;5(6):742-9
   Google Scholar
• Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol 2012;23(2):96-104
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120(6):701-13. discussion 829-30
   PubMed Web of Science ®Google Scholar
• Shaya FT. Compliance with medicine. Ophthalmol Clin North Am 2005;18(4):611-17
   Google Scholar
• Stryker JE, Beck AD, Primo SA, et al. An exploratory study of factors influencing glaucoma treatment adherence. J Glaucoma 2010;19(1):66-72
   PubMed Web of Science ®Google Scholar
• Quek DT, Ong GT, Perera SA, et al. Persistence of patients receiving topical glaucoma monotherapy in an Asian population. Arch Ophthalmol 2011;129(5):643-8
   PubMedGoogle Scholar
• Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol 2010;4:1-9
   PubMedGoogle Scholar
• Goni F. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2004;15(5):581-90
   Google Scholar
• Solish AM, DeLucca PT, Cassel DA, et al. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma 2004;13(2):149-57
   Google Scholar
• Diestelhorst M, Larsson LI. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology 2006;113(1):70-6
   PubMed Web of Science ®Google Scholar
• Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma 2005;14(5):392-9
   PubMed Web of Science ®Google Scholar
• Hommer A. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol 2006;17(1):53-62
   Google Scholar
• Nagayama M, Nakajima T, Ono J. Safety and efficacy of a fixed versus unfixed brinzolamide/timolol combination in Japanese patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2014;8:219-28
   Google Scholar
• Timolol maleate ophthalmic solution [package insert]. Falcon Pharmaceuticals, Ltd; Fort Worth, TX: 2004
   Google Scholar
• FDA Approves Simbrinza for Glaucoma, Ocular Hypertension. Medscape; 2013. Available from: http://www.medscape.com/viewarticle/803064
   Google Scholar
• Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol 1996;41:S19-26
   PubMed Web of Science ®Google Scholar
• Silver LH. Clinical efficacy and safety of brinzolamide (Azopt™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 1998;126(3):400-8
   PubMed Web of Science ®Google Scholar
• Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2009;18(4):293-300
   PubMed Web of Science ®Google Scholar
• Day DG, Hollander DA. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Curr Med Res Opin 2008;24(5):1435-42
   PubMed Web of Science ®Google Scholar
• Bournias TE, Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology 2009;116(9):1719-24
   PubMed Web of Science ®Google Scholar
• Zhou Z, Althin R, Sforzolini BS, Dhawan R. Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom. Br J Ophthalmol 2004;88(11):1391-4
   Google Scholar
• Skalicky SE, Goldberg I. Adherence and Persistence: the Challenges for Glaucoma Medical Therapy. The Asia-Pacific Journal of Ophthalmology 2013;2(6):356-61
   Google Scholar
• Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 2005;112(6):953-61
   PubMed Web of Science ®Google Scholar
• Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995;26(3):233-6
   PubMedGoogle Scholar
• Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005;112(5):863-8
   PubMed Web of Science ®Google Scholar
• Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging 2007;24(12):1007-16
   PubMed Web of Science ®Google Scholar
• Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology 2006;113(3):431-6
   PubMed Web of Science ®Google Scholar
• Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol 2012;153(1):1-9; e2
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002;86(4):418-23
   PubMed Web of Science ®Google Scholar
• Hollo G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother 2014;15(12):1737-47
   PubMed Web of Science ®Google Scholar
• Roughead EE, Kalisch LM, Pratt NL, et al. Managing glaucoma in those with co-morbidity: not as easy as it seems. Ophthalmic Epidemiol 2012;19(2):74-82
   PubMed Web of Science ®Google Scholar
• Cvetkovic RS, Perry CM. Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 2003;20(12):919-47
   Google Scholar
• Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 1998;12(3):225-41
   PubMed Web of Science ®Google Scholar
• Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113(12):1514-17
   PubMedGoogle Scholar
• Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 1999;128(1):8-14
   PubMed Web of Science ®Google Scholar
• DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol 2000;44(Suppl 2):S119-29
   PubMed Web of Science ®Google Scholar
• SIMBRINZA™ (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% [package insert]. Alcon Laboratories, Inc; Fort Worth, TX: 2013
   Google Scholar
• Centre for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review. 2013. Available from: www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204251Orig1s000ClinPharmR.pdf [Cited 3 July 2013]
   Google Scholar
• Hall R HG, Baker J, Stafford G, et al. Brinzolamide: Analytical Profiles of Drug Substances and Excipients. Academic Press; San Diego, CA: 1999
   Google Scholar
• Acheampong AA, Shackleton M, Tang-Liu DD. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos 1995;23(7):708-12
   PubMed Web of Science ®Google Scholar
• Acheampong A, Tang-Liu DD. Measurement of brimonidine concentrations in human plasma by a highly sensitive gas chromatography/mass spectrometric assay. J Pharm Biomed Anal 1995;13(8):995-1002
   Google Scholar
• Nguyen QH, McMenemy MG, Realini T, et al. Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%. J Ocul Pharmacol Ther 2013;29(3):290-7
   PubMed Web of Science ®Google Scholar
• Whitson JT, Realini T, Nguyen QH, et al. Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension. Clin Ophthalmol 2013;7:1053-60
   PubMedGoogle Scholar
• Katz G, Dubiner H, Samples J, et al. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%. JAMA Ophthalmol 2013;131(6):724-30
   PubMed Web of Science ®Google Scholar
• Realini T, Nguyen QH, Katz G, DuBiner H. Fixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies. Eye (Lond) 2013;27(7):841-7
   PubMed Web of Science ®Google Scholar
• Aung T, Laganovska G, Paredes T, et al. Twice-Daily Brinzolamide/Brimonidine Fixed Combination vs Brinzolamide or Brimonidine in Open-Angle Glaucoma or Ocular Hypertension. Ophthalmology 2014. Epub ahead of print Available from: http://dx.doi.org/10.1016/j.ophtha.2014.06.022
   Google Scholar
• Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol 1998;126(3):400-8
   PubMed Web of Science ®Google Scholar
• Sall K. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Surv Ophthalmol 2000;44(Suppl 2):S155-62
   PubMed Web of Science ®Google Scholar
• March WF, Ochsner KI. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. Am J Ophthalmol 2000;129(2):136-43
   Google Scholar
• Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol 1996;41(Suppl 1):S19-26
   PubMed Web of Science ®Google Scholar
• Fudemberg SJ, Batiste C, Katz LJ. Efficacy, safety, and current applications of brimonidine. Expert Opin Drug Saf 2008;7(6):795-9
   PubMed Web of Science ®Google Scholar
• Yu M, Li Y, Ge J. [The ocular hypotensive effect and safety of 0.2% brimonidine]. Yan Ke Xue Bao 2001;17(4):235-8
   Google Scholar
• Melamed S, David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. Clin Ther 2000;22(1):103-11
   PubMed Web of Science ®Google Scholar
• Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS 2001;5(5):281-4
   PubMed Web of Science ®Google Scholar
• Shin DH, Feldman RM, Sheu WP. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 2004;111(2):276-82
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Airaksinen PJ, Getson AJ, et al. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004;82(1):42-8
   Google Scholar
• Hollo G, Bozkurt B, Irkec M. Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother 2009;10(12):2015-24
   PubMed Web of Science ®Google Scholar
• Florez A, Roson E, Conde A, et al. Toxic epidermal necrolysis secondary to timolol, dorzolamide, and latanoprost eyedrops. J Am Acad Dermatol 2005;53(5):909-11
   Google Scholar
• Kim JW, Shin SY. Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome Caused by Topical Ophthalmic Use of Dorzolamide. Korean Journal of Dermatology 2009;47(3):317-21
   Google Scholar
• Chun JS, Yun SJ, Lee JB, et al. Toxic epidermal necrolysis induced by the topical carbonic anhydrase inhibitors brinzolamide and dorzolamide. Annals of Dermatology 2008;20(4):260-2
   Google Scholar
• Martin XD, Danese M. Dorzolamide-induced immune thrombocytopenia: a case report and literature review. J Glaucoma 2001;10(2):133-5
   Google Scholar
• Goyal R, Ram AR. Brimonidine tartarate 0.2% (Alphagan) associated granulomatous anterior uveitis. Eye (Lond) 2000;14(Pt 6):908-10
   PubMedGoogle Scholar
• Byles DB, Frith P, Salmon JF. Anterior uveitis as a side effect of topical brimonidine. Am J Ophthalmol 2000;130(3):287-91
   PubMed Web of Science ®Google Scholar
• Cates CA, Jeffrey MN. Granulomatous anterior uveitis associated with 0.2% topical brimonidine. Eye (Lond) 2003;17(5):670-1
   PubMed Web of Science ®Google Scholar
• Velasque L, Ducousso F, Pernod L, et al. Anterior uveitis and topical brimonidine: a case report. J Fr Ophtalmol 2004;27(10):1150-2
   Google Scholar
• Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol 1995;113(1):77-83
   PubMedGoogle Scholar
• Al-Shahwan S, Al-Torbak AA, Turkmani S, et al. Side-effect profile of brimonidine tartrate in children. Ophthalmology 2005;112(12):2143
   PubMed Web of Science ®Google Scholar
• Mungan NK, Wilson TW, Nischal KK, et al. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers. Journal of American Association for Pediatric Ophthalmology and Strabismus 2003;7(1):69-70
   Google Scholar
• Alcon Research. A Comfort Study of Brinzolamide 1% Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%. 2011. Available from: http://ClinicalTrials.gov/show/NCT01426867 [Cited November 2011]
   Google Scholar
• Alcon R. Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension. 2013. Available from: http://ClinicalTrials.gov/show/NCT01309204 [Cited January 2013]
   Google Scholar
• Alcon R. Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination. 2010. Available from: http://ClinicalTrials.gov/show/NCT00961649 [Cited February 2010]
   Google Scholar
• Alcon Research. Effect of SIMBRINZA™ As an Added Therapy to TRAVATAN Z®. 2014. Available from: http://ClinicalTrials.gov/show/NCT01937299 [Cited April 2014]
   Google Scholar
• Alcon Research. Effect of SIMBRINZA™ As an Added Therapy to a Prostaglandin Analogue. 2014. Available from: http://ClinicalTrials.gov/show/NCT01937312 [Cited May 2014]
   Google Scholar
• Alcon Research. Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension. 2014. Available from: http://ClinicalTrials.gov/show/NCT01978600 [Cited March 2014]
   Google Scholar